Kelsey L Besse1, Jaime M Preussler1, Elizabeth A Murphy1, Ellen M Denzen1, Michael C Lill1, Jeffrey W Chell1, Mary K Senneka1, Navneet S Majhail1, Eric P Williams2. 1. National Marrow Donor Program; Center for International Blood and Marrow Transplant Research, Minneapolis, MN; Cedars-Sinai Medical Center, Los Angeles, CA; and Cleveland Clinic, Cleveland, OH. 2. National Marrow Donor Program; Center for International Blood and Marrow Transplant Research, Minneapolis, MN; Cedars-Sinai Medical Center, Los Angeles, CA; and Cleveland Clinic, Cleveland, OH eric.williams@nmdp.org.
Abstract
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is an increasingly used therapy for many patients with hematologic malignancies and other marrow failure or immune system disorders. The purpose of this study was to quantify and visualize both the demand and unmet need for HCT. METHODS: HCT use for 2012 was described using the Center for International Blood and Marrow Transplant Research registry. Potential demand for HCT was calculated using 2012 SEER data and published literature for HCT-treatable conditions. Point locations of transplant centers were geocoded using geographic information system (GIS) software; Thiessen polygons were created to establish adult (age 20 to 74 years) and pediatric (age 0 to 19 years) market areas. Market-area population estimates were calculated using 2012 population estimates by age aggregated by census block. RESULTS: US market areas for HCTs were identified separately for transplant centers treating adult (n = 62) and pediatric patients (n = 52). Overall HCT demand among adults was 16,096, with an unmet need for HCTs of 10,276 patients. For pediatric patients, the total demand was 4,561, with an unmet need of 3,213 potential recipients. Evaluation of adult and pediatric market areas indicated that the largest unmet needs tended to be in areas with large populations. CONCLUSION: Market-area maps and statistics developed using GIS will help communicate the unmet need for HCT, inform policy, and assist transplant centers in planning for the anticipated growth in HCT use.
PURPOSE: Allogeneic hematopoietic cell transplantation (HCT) is an increasingly used therapy for many patients with hematologic malignancies and other marrow failure or immune system disorders. The purpose of this study was to quantify and visualize both the demand and unmet need for HCT. METHODS: HCT use for 2012 was described using the Center for International Blood and Marrow Transplant Research registry. Potential demand for HCT was calculated using 2012 SEER data and published literature for HCT-treatable conditions. Point locations of transplant centers were geocoded using geographic information system (GIS) software; Thiessen polygons were created to establish adult (age 20 to 74 years) and pediatric (age 0 to 19 years) market areas. Market-area population estimates were calculated using 2012 population estimates by age aggregated by census block. RESULTS: US market areas for HCTs were identified separately for transplant centers treating adult (n = 62) and pediatric patients (n = 52). Overall HCT demand among adults was 16,096, with an unmet need for HCTs of 10,276 patients. For pediatric patients, the total demand was 4,561, with an unmet need of 3,213 potential recipients. Evaluation of adult and pediatric market areas indicated that the largest unmet needs tended to be in areas with large populations. CONCLUSION: Market-area maps and statistics developed using GIS will help communicate the unmet need for HCT, inform policy, and assist transplant centers in planning for the anticipated growth in HCT use.
Authors: André Tichelli; Hubert Schrezenmeier; Gérard Socié; Judith Marsh; Andrea Bacigalupo; Ulrich Dührsen; Anke Franzke; Michael Hallek; Eckhard Thiel; Martin Wilhelm; Britta Höchsmann; Alain Barrois; Kim Champion; Jakob R Passweg Journal: Blood Date: 2011-01-13 Impact factor: 22.113
Authors: Shu-Chih Su; Norma Kanarek; Michael G Fox; Alla Guseynova; Shirley Crow; Steven Piantadosi Journal: Clin Cancer Res Date: 2010-01-26 Impact factor: 12.531
Authors: Navneet S Majhail; Nancy A Omondi; Ellen Denzen; Elizabeth A Murphy; J Douglas Rizzo Journal: Biol Blood Marrow Transplant Date: 2009-12-28 Impact factor: 5.742